会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Recombinantly expressed insulin polypeptides and uses thereof
    • 重组表达的胰岛素多肽及其用途
    • US09074015B2
    • 2015-07-07
    • US13811910
    • 2011-07-22
    • Thomas M. LancasterSylaja MurikipudiRassol LaleauTodd C. Zion
    • Thomas M. LancasterSylaja MurikipudiRassol LaleauTodd C. Zion
    • C07K14/62A61K38/28
    • C07K14/62A61K38/28
    • The present disclosure provides recombinantly expressed insulin polypeptides that comprise an N-linked glycan motif. The N-linked glycan motif is not present in wild-type insulins and enables the recombinant expression of glycosylated insulin polypeptides (e.g., in yeast cells). Based on results obtained with synthetic glycosylated insulin conjugates we predict that when these recombinant glycosylated insulin polypeptides are administered to a mammal, at least one pharmacokinetic or pharmacodynamic property of the glycosylated insulin polypeptide will be sensitive to serum concentrations of glucose (or an exogenous saccharide such as alpha-methyl mannose). Exemplary insulin polypeptides, polynucleotides encoding these insulin polypeptides, glycosylated insulin polypeptides, pharmaceutical formulations and sustained release formulations are provided in addition to methods of use and preparation.
    • 本公开提供包含N-连接的聚糖基序的重组表达的胰岛素多肽。 N-连接的聚糖基序不存在于野生型胰岛素中,并且能够重组表达糖基化的胰岛素多肽(例如,在酵母细胞中)。 基于用合成糖基化胰岛素缀合物获得的结果,我们预测当将这些重组糖基化胰岛素多肽施用于哺乳动物时,糖基化胰岛素多肽的至少一种药代动力学或药效学性质将对葡萄糖(或外源性糖类) 作为α-甲基甘露糖)。 除了使用和制备方法之外,还提供示例性的胰岛素多肽,编码这些胰岛素多肽的多核苷酸,糖基化胰岛素多肽,药物制剂和持续释放制剂。
    • 7. 发明授权
    • Polynucleotide aptamer-based cross-linked materials and uses thereof
    • 基于多核苷酸适体的交联材料及其用途
    • US08603529B2
    • 2013-12-10
    • US13145531
    • 2010-01-27
    • Todd C. ZionThomas M. Lancaster
    • Todd C. ZionThomas M. Lancaster
    • A61K9/14A61K38/28C07H21/04
    • C12N15/111A61K47/549C12N2310/16C12N2310/51
    • In one aspect, the disclosure provides cross-linked materials that include multivalent polynucleotide aptamers that bind a target molecule; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with the target molecule for binding with the aptamers and wherein conjugates are cross-linked within the material as a result of non-covalent interactions between aptamers and affinity ligands on different conjugates. These materials are designed to release amounts of conjugate in response to desired concentrations of the target molecule. Depending on the end application, in various embodiments, the conjugates may also include a drug and/or a detectable label. The drug, detectable label and affinity ligands may be covalently or non-covalently bound to the conjugate framework.
    • 一方面,本公开提供交联材料,其包括结合目标分子的多价多核苷酸适体; 以及包含与缀合物框架结合的两个或更多个分离的亲和配体的缀合物,其中所述两个或更多个亲和配体与靶分子竞争与适配体结合,并且其中结合物由于非共价键而在材料内交联 适体与亲和配体在不同共轭物上的相互作用。 这些材料被设计成响应于目标分子的所需浓度释放结合物的量。 根据最终应用,在各种实施方案中,缀合物还可以包括药物和/或可检测标记。 药物,可检测的标记和亲和配体可以共价或非共价结合到缀合物框架。
    • 8. 发明授权
    • Soluble non-depot insulin conjugates and uses thereof
    • 可溶性非仓库胰岛素缀合物及其用途
    • US08569231B2
    • 2013-10-29
    • US13257507
    • 2010-01-27
    • Todd C. ZionThomas M. Lancaster
    • Todd C. ZionThomas M. Lancaster
    • A61K38/28A61P3/10
    • C07K14/62A61K38/28A61K47/549A61K47/6415C07K14/4713C07K14/4743C07K14/65
    • In one aspect, the disclosure provides a conjugate comprising an insulin molecule having an A-chain and a B-chain; an affinity ligand covalently bound to the A-chain; and a monovalent glucose binding agent covalently bound to the B-chain, wherein the affinity ligand competes with glucose for non-covalent binding with the monovalent glucose binding agent. In the absence of glucose, the monovalent glucose binding agent binds the affinity ligand to produce a “closed” inactive form of the insulin molecule. When free glucose is added, it competes with the affinity ligand for binding with the monovalent glucose binding agent to produce an “open” active form of the insulin molecule. The monovalent glucose binding agent and affinity ligand are covalently bound to the insulin molecule. The disclosure also provides methods of using these conjugates and methods of making these conjugates. In another aspect, the disclosure provides exemplary conjugates. The disclosure also provides alternative conjugates that are not necessarily activated by glucose.
    • 一方面,本公开提供了包含具有A链和B链的胰岛素分子的缀合物; 与A链共价结合的亲和配体; 与B链共价结合的一价葡萄糖结合剂,其中亲和配体与葡萄糖竞争与单价葡萄糖结合剂的非共价结合。 在没有葡萄糖的情况下,一价葡萄糖结合剂结合亲和配体以产生胰岛素分子的“封闭”无活性形式。 当加入游离葡萄糖时,其与亲和配体竞争与单价葡萄糖结合剂结合以产生胰岛素分子的“开放”活性形式。 一价葡萄糖结合剂和亲和配体与胰岛素分子共价结合。 本公开还提供了使用这些缀合物的方法和制备这些缀合物的方法。 在另一方面,本公开提供了示例性缀合物。 本公开还提供了不一定被葡萄糖激活的替代共轭物。